Cancer survivors face a new threat: heart damage caused by the very treatments that saved their lives. While therapies like chemotherapy, radiation, and immunotherapy can be lifesaving, they often cause silent, long-term cardiac harm that goes undetected until it’s too late. ViviScout addresses this urgent gap with a precision wearable platform that provides continuous, real-time heart monitoring tailored to each survivor’s treatment history. Focused on high-risk cancers like breast, lymphoma, and leukemia, ViviScout empowers early detection and intervention to prevent heart failure and protect survivor health. Because beating cancer should be the beginning of a strong, healthy future—not the start of a new risk.
SHARE:
Cancer survivors fought hard for their lives—now it’s our turn to protect the future they’ve earned. But cancer treatments have advanced faster than the systems meant to protect survivors. Today, more people beat cancer than ever, but many are left vulnerable to a new threat: heart disease caused by the very therapies that saved their lives.
Traditional treatments like chemotherapy and radiation, and newer options like immunotherapy and targeted drugs, can cause silent, lasting heart damage. Yet most survivors only discover problems after symptoms appear, when damage is often irreversible. This gap puts millions at risk for preventable heart failure, cardiotoxicity, and shortened lives.
ViviScout is working to close that gap. Our platform provides continuous, real-time heart monitoring after cancer treatment, helping doctors detect cardiotoxicity early and act before it’s too late. Our urgent focus is post-treatment monitoring for survivors of breast cancer, lymphoma, lung cancer, leukemia, and colorectal cancer, groups known to face sharply higher cardiac risks. Studies show survivors are 52% more likely to develop heart failure, compared to the general population. The risks persist whether treatment involves anthracyclines, trastuzumab, checkpoint inhibitors, or targeted therapies.
Unlike general fitness wearables, ViviScout is designed for heart monitoring precision that has never existed before on a wearable, tailoring insights to a survivor’s cancer history and treatment path.
Early action saves lives: adjusting therapies, prescribing heart-protective medications, and guiding survivors toward longer, stronger futures. At ViviScout, we believe surviving cancer isn’t enough. Survivors deserve a future they can trust. They fought to survive. Now it’s our job to protect what they’ve won.
Our next milestone is to complete our clinical test platform, which is already in development. ViviScout is building a system for continuous, real-time heart monitoring to better protect cancer survivors. Unlike traditional checkups, our technology will give doctors daily insights into a patient’s heart health. Existing wearables aren’t built for clinical-grade detection, but our system will catch subtle, early signs of heart damage. With support, we can complete the platform and begin clinical validation to help millions of survivors avoid preventable cardiac risks.
Thanks to early supporters, we’ve built a strong foundation, including funding from an investor who owns a cancer center. We’re a small, passionate team developing real-time heart monitoring technology to protect cancer survivors. With a trusted manufacturing partner, we’re focused on creating safe, comfortable, and clinically meaningful devices. Your support can unlock matching grants from organizations like the NIH and American Heart Association, multiplying your impact. It also signals confidence to impact investors and hospitals, helping us launch clinical trials and reach more survivors.
If ViviScout’s technology were to disappear, millions of cancer survivors could be left unprotected, surviving cancer only to face heart disease they never saw coming.
Without early detection, too many survivors will suffer preventable heart failure, strokes, and shortened lives. Families who have already fought so hard would lose loved ones to risks other than cancer.
This is more than a missed innovation — it’s a missed chance to rewrite what survivorship truly means. With your support, we can make sure that beating cancer is just the beginning of a long, healthy life.
CEO & Founder
AI/ML and Technology
Product Development
$200000 donated by Anonymous
$200000 donated by Anonymous
